Last reviewed: June 11, 2026

Last updated: June 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, a GLP-1 receptor agonist originally developed for type 2 diabetes, has gained attention in addiction medicine for its potential to curb alcohol cravings. A 2023 Yale study found that patients taking semaglutide reported reduced desire to drink, and emerging evidence suggests the drug may work by regulating dopamine signaling in reward centers of the brain. While research is still early, this finding opens new therapeutic possibilities for people struggling with alcohol use disorder.

How Semaglutide May Affect Alcohol Cravings

Semaglutide binds to GLP-1 receptors found throughout the brain, including regions responsible for reward and motivation. When these receptors activate, they may dampen the brain's response to addictive stimuli—including alcohol. This mechanism differs from traditional addiction medications like naltrexone, which work primarily by blocking opioid receptors rather than modulating appetite and reward pathways.

In the Yale clinical trial, patients treated with semaglutide showed a measurable decrease in heavy drinking days over 16 weeks compared to placebo. The drug did not eliminate the desire to drink entirely, but participants reported lower cravings and greater control over consumption. This suggests semaglutide may work best as part of a comprehensive treatment plan that includes counseling and behavioral support, not as a standalone cure.

Key Research on GLP-1 Therapy and Alcohol Use Disorder

The Yale study published in 2023 enrolled adults with moderate to severe alcohol use disorder and tested semaglutide doses up to 2.4 mg weekly. Results showed that participants on active semaglutide reduced heavy drinking days by approximately 50% compared to 24% in the placebo group—a clinically significant finding. The medication was generally well-tolerated, with nausea and gastrointestinal side effects being the most common complaints.

Preclinical research in animal models has shown that GLP-1 receptor activation reduces alcohol self-administration and may reverse some alcohol-related brain changes. Human neuroimaging studies are ongoing, but preliminary data suggest semaglutide may restore balance to dopamine circuits dysregulated by chronic alcohol use. These findings remain promising but preliminary, and more large-scale trials are needed to confirm efficacy and identify which patients benefit most.

Important Differences Between Semaglutide and Traditional Alcohol Medications

Currently approved medications for alcohol use disorder—including naltrexone, acamprosate, and disulfiram—work through different neurochemical pathways than semaglutide. Naltrexone blocks opioid receptors to reduce reward from drinking, while disulfiram creates an unpleasant reaction if alcohol is consumed. Semaglutide's approach targets the broader reward and appetite system, potentially offering a novel option for patients who have not responded to existing therapies.

Unlike disulfiram, semaglutide does not cause an aversive reaction to alcohol, so it requires patient commitment and motivation to remain effective. It also does not target the hypothetical alcohol-specific 'addiction center' in the brain but instead restores overall homeostasis in appetite and reward circuits. This broader mechanism may explain why some patients report improved impulse control and reduced cravings across multiple behaviors, not just drinking.

Considering Personalized GLP-1 Therapy for Alcohol Recovery

PlexusDx compounded semaglutide injection offers a way to explore GLP-1 therapy under medical supervision, starting at just $149 per month with no insurance required. The medication comes from licensed 503A compounding pharmacies and is available across all 50 states, making it accessible to patients regardless of insurance status or geographic location. PlexusDx also accepts HSA and FSA funds, further lowering out-of-pocket costs for eligible patients.

For patients interested in understanding their individual response to GLP-1 therapy, PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after first month), which maps 14 biological pathways and 49 peptides linked to appetite, reward, and metabolism. Key variants like GLP1R rs6923761 and GIPR rs1800437 can inform whether your brain's GLP-1 signaling system is likely to respond robustly to semaglutide therapy. This personalized approach helps optimize treatment selection and dosing strategy from the start.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is semaglutide approved by the FDA for treating alcohol use disorder?

No, semaglutide is not FDA-approved for alcohol use disorder; approval exists only for type 2 diabetes and weight management. However, emerging clinical trial evidence suggests potential benefit, and some addiction specialists are exploring it off-label. PlexusDx compounds semaglutide in licensed 503A pharmacies under physician supervision for patients interested in evidence-based off-label use.

What does the research actually show about semaglutide and alcohol cravings?

A 2023 Yale study found that semaglutide reduced heavy drinking days by approximately 50% compared to 24% in placebo-treated patients over 16 weeks. Participants reported lower cravings and better drinking control, suggesting the drug works by modulating brain reward pathways rather than creating aversion. Results are promising but preliminary; larger trials are underway to confirm long-term efficacy.

How much does compounded semaglutide cost at PlexusDx?

PlexusDx compounded semaglutide injection starts at $149 per month with no flat per-compound pricing increases—your dose may go up, but your price stays flat. No insurance is required, and HSA/FSA funds are accepted. Service is available across all 50 states.

Can semaglutide replace traditional alcohol addiction treatments like naltrexone?

Semaglutide works through a different mechanism than naltrexone and may benefit patients who have not responded to existing medications. However, it is most effective as part of comprehensive treatment that includes counseling, support groups, and behavioral intervention. Your prescribing physician can help determine whether semaglutide, naltrexone, or a combination approach is right for your situation.

Can the Precision Peptide Genetic Test predict how I'll respond to semaglutide for alcohol recovery?

PlexusDx Precision Peptide Genetic Test analyzes 14 biological pathways including GLP-1 receptor signaling and dopamine-related variants. While the test identifies genetic predispositions affecting reward sensitivity and appetite control, response to semaglutide for alcohol use involves complex neurobiology. Genetic insights help personalize dosing and expectations, but clinical response ultimately requires trial under medical supervision.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves